{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:08:48Z","timestamp":1791198528718,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001543","name":"Neurological Foundation of New Zealand","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001543","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Australian National Health and Medical Research Council"},{"name":"University of Auckland Health Research Doctoral Scholarship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.neuroscience.2010.06.056","type":"journal-article","created":{"date-parts":[[2010,7,2]],"date-time":"2010-07-02T08:38:20Z","timestamp":1278059900000},"page":"324-336","source":"Crossref","is-referenced-by-count":64,"title":["Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice"],"prefix":"10.1016","volume":"170","author":[{"given":"M.J.","family":"Dowie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.B.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.M.","family":"Faull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2010.06.056_bib1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nbd.2004.04.001","article-title":"A cell-based screen for drugs to treat Huntington's disease","volume":"16","author":"Aiken","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1535-7597.2004.04501.x","article-title":"Endocannabinoids and their implications for epilepsy","volume":"4","author":"Alger","year":"2004","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejphar.2006.03.041","article-title":"Co-distribution of the cannabinoid CB1 receptor and the 5-HT transporter in the rat amygdale","volume":"537","author":"Ashton","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1471-4159.2004.02839.x","article-title":"Tissue transglutaminase contributes to disease progression in the R6\/2 Huntington's disease mouse model via aggregate-independent mechanisms","volume":"92","author":"Bailey","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.wco.0000084223.82329.bb","article-title":"Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?","volume":"16","author":"Bates","year":"2003","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib6","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1073\/pnas.0511256103","article-title":"Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases","volume":"103","author":"Bodner","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brainres.2004.01.021","article-title":"Early exploratory behavior abnormalities in R6\/1 Huntington's disease transgenic mice","volume":"1005","author":"Bolivar","year":"2004","journal-title":"Brain Res"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1523\/JNEUROSCI.23-03-00961.2003","article-title":"Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease","volume":"23","author":"Cepeda","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/jnr.20344","article-title":"Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF","volume":"78","author":"Cepeda","year":"2004","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib10","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1073\/pnas.95.11.6480","article-title":"Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene","volume":"95","author":"Cha","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nbd.2007.07.028","article-title":"Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo","volume":"29","author":"Charvin","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0028-3908(98)00208-1","article-title":"Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors","volume":"38","author":"Cheer","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0304-3959(01)00454-7","article-title":"CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain","volume":"96","author":"Clayton","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/384083a0","article-title":"Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides","volume":"384","author":"Cravatt","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bcp.2005.05.011","article-title":"Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels","volume":"70","author":"de Lago","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.mcn.2006.12.005","article-title":"Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation","volume":"34","author":"Docagne","year":"2007","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.neuroscience.2009.06.014","article-title":"Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease","volume":"163","author":"Dowie","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib19","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1098\/rspb.1998.0543","article-title":"A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain","volume":"265","author":"Egertova","year":"1998","journal-title":"Proc Biol Sci"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1124\/jpet.104.078980","article-title":"Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation","volume":"313","author":"Fegley","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib22","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.neuroscience.2008.11.024","article-title":"Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression","volume":"158","author":"Giralt","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0306-4522(93)90352-G","article-title":"Loss of cannabinoid receptors in the substantia nigra in Huntington's disease","volume":"56","author":"Glass","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0306-4522(03)00595-5","article-title":"Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors","volume":"123","author":"Glass","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib26","doi-asserted-by":"crossref","first-page":"18620","DOI":"10.1073\/pnas.0509591102","article-title":"Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis","volume":"102","author":"Gobbi","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0306-4522(01)00509-7","article-title":"Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain","volume":"109","author":"Hermann","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib29","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hipo.20647","article-title":"Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus","volume":"20","author":"Hill","year":"2010","journal-title":"Hippocampus"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0033291799002871","article-title":"The molecular biology of Huntington's disease","volume":"31","author":"Ho","year":"2001","journal-title":"Psychol Med"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"9","author":"Kathuria","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1248\/bpb.21.224","article-title":"Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor","volume":"21","author":"Kimura","year":"1998","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib34","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bjp.0701918","article-title":"Modulation of GABA(A) receptors and inhibitory synaptic currents by the endogenous CNS sleep regulator cis-9,10-octadecenoamide (cOA)","volume":"124","author":"Lees","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib36","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1523\/JNEUROSCI.4465-07.2008","article-title":"Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus","volume":"28","author":"Ludanyi","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pneurobio.2006.11.006","article-title":"The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases","volume":"81","author":"Maccarrone","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nn2042","article-title":"Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum","volume":"11","author":"Maccarrone","year":"2008","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00008877-200402000-00003","article-title":"Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats","volume":"15","author":"Marco","year":"2004","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib41","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/j.1471-4159.2007.04961.x","article-title":"CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A\/C receptors","volume":"103","author":"Mato","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib42","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1523\/JNEUROSCI.4320-04.2005","article-title":"Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice","volume":"25","author":"Mazarakis","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib43","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1093\/hmg\/ddg295","article-title":"Pathogenesis of polyglutamine disorders: aggregation revisited","volume":"2","author":"Michalik","year":"2003","journal-title":"Hum Mol Genet 12 Spec No"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0014-2999(95)00151-A","article-title":"Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata","volume":"279","author":"Miller","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mrdd.1022","article-title":"Juvenile onset Huntington's disease\u2014clinical and research perspectives","volume":"7","author":"Nance","year":"2001","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.0953-816X.2000.01379.x","article-title":"Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6\/1 Huntington transgenic mice","volume":"13","author":"Nicniocaill","year":"2001","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib47","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.nbd.2007.11.006","article-title":"Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice","volume":"29","author":"Nithianantharajah","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib48","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/hmg\/ddn385","article-title":"Altered serotonin receptor expression is associated with depression-related behavior in the R6\/1 transgenic mouse model of Huntington's disease","volume":"18","author":"Pang","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib50","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/brain\/awg224","article-title":"Cannabinoids inhibit neurodegeneration in models of multiple sclerosis","volume":"126","author":"Pryce","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2008.08.012","article-title":"Anandamide effects on 5-HT(3) receptors in vivo","volume":"596","author":"Racz","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14660820310016813","article-title":"Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid","volume":"5","author":"Raman","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ana.410360406","article-title":"Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus","volume":"36","author":"Richfield","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib54","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/sj.bjp.0705467","article-title":"Anandamide and vanilloid TRPV1 receptors","volume":"140","author":"Ross","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","article-title":"Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders","volume":"421","author":"Sanchez","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib56","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/exnr.1998.7005","article-title":"Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein","volume":"156","author":"Sieradzan","year":"1999","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1615\/CritRevNeurobiol.v15.i2.10","article-title":"Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids","volume":"15","author":"Sim-Selley","year":"2003","journal-title":"Crit Rev Neurobiol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib58","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1124\/mol.105.019612","article-title":"Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration","volume":"70","author":"Sim-Selley","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib59","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1523\/JNEUROSCI.1658-03.2004","article-title":"Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism","volume":"24","author":"Spires","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0306-4522(97)00597-6","article-title":"Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum","volume":"85","author":"Szabo","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib61","doi-asserted-by":"crossref","first-page":"14115","DOI":"10.1073\/pnas.94.25.14115","article-title":"Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide","volume":"94","author":"Thomas","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib62","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/(SICI)1097-4547(19971215)50:6<1047::AID-JNR16>3.0.CO;2-1","article-title":"Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system","volume":"50","author":"Thomas","year":"1997","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib63","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/35008142","article-title":"Delaying the onset of Huntington's in mice","volume":"404","author":"van Dellen","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2202-9-34","article-title":"Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease","volume":"9","author":"van Dellen","year":"2008","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.nbd.2009.08.012","article-title":"Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity","volume":"36","author":"Xifro","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2010.06.056_bib67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0169-328X(98)00232-0","article-title":"Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions","volume":"62","author":"Zhuang","year":"1998","journal-title":"Brain Res Mol Brain Res"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452210009280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452210009280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T14:11:52Z","timestamp":1740233512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452210009280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0306452210009280"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2010.06.056","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}